Details

Autor(en) / Beteiligte

• Parker, C
• Nilsson, S
• Heinrich, D
• Helle, S.I
• O'Sullivan, J.M
• Fosså, S.D
• Chodacki, A
• Wiechno, P
• Logue, J
• Seke, M
• Widmark, A
• Johannessen, D.C
• Hoskin, P
• Bottomley, D
• James, N.D
• Solberg, A
• Syndikus, I
• Kliment, J
• Wedel, S
• Boehmer, S
• Dall'Oglio, M
• Franzén, L
• Coleman, R
• Vogelzang, N.J
• O'Bryan-Tear, C.G
• Staudacher, K
• Garcia-Vargas, J
• Shan, M
• Bruland, Ø.S
• Sartor, O

Titel

Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

Ist Teil von

• The New England journal of medicine, 2013-07, Vol.369 (3), p.213-223

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2013

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• In a study involving men with castration-resistant prostate cancer and bone metastases, the alpha emitter radium-223 significantly prolonged survival, as compared with placebo, and was associated with fewer adverse events. More than 90% of patients with metastatic castration-resistant prostate cancer have radiologic evidence of bone metastases, which are a major cause of death, disability, decreased quality of life, and increased treatment cost among these patients. 1 , 2 Unlike deaths from many other types of cancer, deaths from prostate cancer are often due to bone disease and its complications. 3 Current bone-targeted therapies have not been shown to improve survival, and the benefits derived from bisphosphonates, denosumab, and existing radioisotope treatments are primarily limited to pain relief and delay of skeletal events. 4 – 13 Radium-223 dichloride (radium-223) is a targeted alpha emitter that selectively . . .